Somwar, Romel
Memorial Sloan Kettering Cancer Center
6 papers on CoChatORCID 0000-0002-5282-6889
Most cited papers
- Verified
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 3,527
- Verified
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer
Schoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. C., Paik, P. K., Offin, M., Arcila, M. E., et al. (2020) · Clinical Cancer Research
Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics
Cited by 411
- Verified
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
Yu, H. A., Suzawa, K., Jordan, E., Zehir, A., Ni, A., Kim, R., Kris, M. G., Hellmann, M. D., Li, B. T., Somwar, R., et al. (2018) · Clinical Cancer Research
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 259
- Verified
RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition
Hayashi, T., Desmeules, P., Smith, R. S., Drilon, A., Somwar, R., & Ladanyi, M. (2018) · Clinical Cancer Research
Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics
Cited by 90
- Verified
Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis
O’Farrell, H., Harbourne, B., Kurlawala, Z., Inoue, Y., Nagelberg, A. L., Martinez, V. D., Lu, D., Oh, M. H., Coe, B. P., Thu, K. L., et al. (2019) · Journal of Thoracic Oncology
Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics
Cited by 23
- Verified
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236
Pfeil, A. J., Zhang, T., Cheng, R., Mattar, M. S., Gomez Marti, J. L., Gili, L., Lai, R., Khodos, I., Master, R. P., Dix, J.-M., et al. (2025) · Clinical Cancer Research
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 3
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free